From: Association between multiple sclerosis, cancer risk, and immunosuppressant treatment: a cohort study
Variable | Exposed to IS | Others |
---|---|---|
Sex (W/M) | 531 (336/195) | 531 (359/172) |
Mean age at onset (years +/− SD) | 29 (10) | 30 (10) |
Mean age at treatment start (years +/− SD) | 29.4 (9.9) | 40 (13.5) |
Mean disease duration (SD) | 19 (9) | 20 (10) |
Mean Follow-up (years +/− SD) for the whole cohort | 9 (5) | 10 (6) |
Mean Follow-up (years +/− SD) for the MX group | 8 (5) | _ |
Mean Follow-up (years +/− SD) for the CP group | 5 (5) | _ |
Mean Follow-up (years +/− SD) for the AZA group | 10 (6) | _ |
Mean treatment duration for the MX group (years) | 1 | _ |
Mean treatment duration for the CP group (years) | 1 | _ |
Mean treatment duration for the AZA group (years) | 4 | _ |